<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Intravenous Tranexamic Acid Combined With Intramyometrial Desmopressin During Laparoscopic Myomectomy: A Randomized Double-Blind Placebo-Controlled Trial

dc.contributor.authorOzbasli, Esra
dc.contributor.authorUnsal, Gozde
dc.contributor.authorDede, Faruk Suat
dc.contributor.authorGungor, Mete
dc.date.accessioned2026-11-05T11:01:13Z
dc.date.issued2026
dc.description.abstractObjective: To evaluate whether intravenous tranexamic acid combined with intramyometrial desmopressin reduces perioperative blood loss during laparoscopic myomectomy. Design: A prospective, randomized, double-blind, placebo-controlled trial. Setting: A tertiary university hospital. Patients: One hundred women undergoing laparoscopic myomectomy for symptomatic uterine fibroids were included in the anticoagulant use, body mass index >= 30 kg/m2, or concomitant surgical procedures were excluded. Interventions: Participants were randomized to receive intravenous tranexamic acid 1 g (n = 50) or placebo (normal saline; n = 50). All patients received intramyometrial desmopressin (30 mcg diluted in 100 mL normal saline). Measurements and Main Results: Median estimated blood loss did not differ significantly between the tranexamic acid and placebo groups (150 mL vs 100 mL; p = .269). Transfusion rates were similar (10% vs 6%; p = .715). Postoperative hemoglobin levels were comparable between groups (p = .505). Surgeon-rated operative difficulty scores were significantly higher in Group I than in Group II (median score: 6 vs 5, p = .016). Multivariable regression identified myoma number (B = 19.09 mL per myoma; 95% CI: 8.31-29.86; p = .001) and myoma diameter (B = 2.02 mL per cm; 95% CI: 0.18 -3.85; p = .032) as independent predictors of blood loss. Increasing age was independently associated with blood transfuConclusion: Tranexamic acid was safe but did not significantly reduce estimated blood loss or the need for transfusion compared with the placebo. Routine combined use is not supported; however, further evaluation in patients with a higher myoma burden may be warranted. Journal of Minimally Invasive Gynecology (2026) 33, 1473-1480.
dc.description.issue10
dc.description.pages1473-1480
dc.description.volume33
dc.identifier.doi10.1016/j.jmig.2026.03.032
dc.identifier.issn1553-4650
dc.identifier.issn1553-4669
dc.identifier.urihttps://doi.org/10.1016/j.jmig.2026.03.032
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10678
dc.identifier.wosWOS:001900415500001
dc.language.isoen
dc.publisherELSEVIER SCIENCE INC
dc.relation.hasversion10.1016/j.jmig.2026.03.032
dc.relation.ispartofJOURNAL OF MINIMALLY INVASIVE GYNECOLOGY
dc.subjectdesmopressin
dc.subjectintraoperative hemorrhage
dc.subjectlaparoscopic myomectomy
dc.subjecttranexamic acid
dc.subjectuterine fibroids
dc.subjectBLOOD-LOSS
dc.subjectWOMEN
dc.subjectObstetrics & Gynecology
dc.titleIntravenous Tranexamic Acid Combined With Intramyometrial Desmopressin During Laparoscopic Myomectomy: A Randomized Double-Blind Placebo-Controlled Trial
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.endPage1480
oaire.citation.issue10
oaire.citation.startPage1473
oaire.citation.volume33
person.identifier.ridD-6301-2016
person.identifier.ridX-4933-2018
person.identifier.ridF-1695-2018

Files

Collections